Fact CheckerSign in

NCT07870668CompletedPhase 4

Intermittent Phentermine for Obesity and Body Composition

Adaptive Pharmacotherapy in Obesity: Intermittent Phentermine Improves Visceral Adiposity and Body Composition

Source: ClinicalTrials.gov · Last updated 13 Oct 2026

Brief summary (registry, in English)

This study evaluated the effects of intermittent phentermine treatment on body fat, estimated visceral adiposity, body composition, and tolerability in adults with overweight or obesity. A total of 600 adults aged 21 to 40 years with a body mass index (BMI) between 27 and 35 kg/m² participated in a single-center, randomized, four-group clinical trial conducted at Hospital Médica Campestre in León, Guanajuato, Mexico. Participants were assigned to lifestyle modification alone or lifestyle modification combined with phentermine at doses of 15 mg, 30 mg, or 37.5 mg daily. Phentermine was administered intermittently using a schedule of three months of treatment followed by one month without medication during a 14-month observation period. All participants received nutritional guidance and physical activity recommendations. Body composition was assessed using bioelectrical impedance analysis and three-dimensional body scanning. The primary outcome was the relative percentage reduction in total body fat from baseline to Month 14. Secondary outcomes included estimated visceral adiposity, waist circumference, lean body mass, body weight, BMI, medication adherence, resting heart rate, blood pressure, treatment-emergent adverse events, and treatment discontinuation. The study aimed to evaluate the dose-response effects of intermittent phentermine on body composition and the balance between efficacy and tolerability.

Status (registry)
Completed
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
600 (actual)
First submitted
6 Oct 2026
Start date
1 Mar 2024
Primary completion date
15 Jan 2026
Lead sponsor
OSCAR MANUEL TORRES FALCON
Diseases
Obesity
NCT number
NCT07870668

What you commit to

  • Study type: Interventional · Phase 4
  • Participants enrolled: 600
  • From 1 Mar 2024 to the primary completion date, 15 Jan 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Known contraindication to sympathomimetic therapy.

Other illness

  • Uncontrolled hypertension.
  • Clinically significant cardiovascular disease.
  • Medical or psychiatric conditions judged to make participation unsafe or compromise protocol adherence.

Other

  • Pregnancy or breastfeeding.

Who the study is looking for

  • Age 21 to 40 years.
  • Body mass index (BMI) 27 to 35 kg/m².
  • Eligible for structured obesity treatment.
  • Willingness to complete serial body-composition assessments.

Age in the registry: 21 years to 40 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Medica Campestre
Coordinator of this site? Confirm its status
LeónMexicoUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.